OPTR Dificid FDA approval. MRNA reverse split vote soon. ALIM mixed shelf

May 27, 2011 No Comments by

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the FDA approved DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD. The label can be found HERE.

Alimera Sciences, Inc. (Nasdaq: ALIM) filed a mixed shelf to the value of $75m after hours.

Marina Biotech, Inc. (Nasdaq: MRNA) announced after hours today they will be voting on July 14 seeking permission for a reverse split of between a ratio of one-for-two and one-for-ten. They will also be voting to increase the number of authorised shares from 90m to 180m. MRNA also effected a 1 for 4 reverse split in July last year.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “OPTR Dificid FDA approval. MRNA reverse split vote soon. ALIM mixed shelf”

Leave a Reply